Mallinckrodt plc, a global leader in specialty pharmaceuticals, is headquartered in Ireland (IE) and operates extensively across North America and Europe. Founded in 1867, the company has a rich history marked by significant milestones in the development of innovative therapies. Specialising in pain management, autoimmune disorders, and critical care, Mallinckrodt offers a range of unique products, including specialty generics and branded medications. Their commitment to addressing unmet medical needs sets them apart in the competitive pharmaceutical landscape. With a strong market position, Mallinckrodt has achieved notable recognition for its contributions to patient care and has established itself as a trusted name in the industry. The company continues to focus on advancing healthcare solutions that improve the quality of life for patients worldwide.
How does Mallinckrodt plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Mallinckrodt plc's score of 57 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Mallinckrodt plc reported total carbon emissions of approximately 80,934,000 kg CO2e for Scope 1, 68,201,000 kg CO2e for Scope 2, and 238,157,000 kg CO2e for Scope 3 emissions. This reflects a slight decrease in Scope 1 emissions from 81,956,000 kg CO2e in 2023 and a reduction in Scope 2 emissions from 73,947,000 kg CO2e in the same year. The company has set ambitious targets to reduce its Scope 1 and Scope 2 emissions to near zero by 2025, demonstrating a commitment to significant climate action. Mallinckrodt's Scope 3 emissions, which include categories such as purchased goods and services (approximately 178,886,000 kg CO2e) and upstream transportation and distribution (about 22,438,000 kg CO2e), highlight the broader impact of its supply chain. The company has not disclosed specific targets for Scope 3 emissions reduction. The emissions data is not cascaded from any parent organization, indicating that these figures are solely attributed to Mallinckrodt plc. The company is headquartered in Ireland (IE) and operates with a revenue of approximately USD 1.98 billion in 2024.
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 80,126,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 82,349,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 |
Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 61% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 75% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mallinckrodt plc has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.